-
公开(公告)号：US08372954B2
公开(公告)日：2013-02-12
申请号：US10451585
申请日：2001-12-21
申请人： Jamshid Tanha , Joycelyn Entwistle , Saran Narang , Michael Dan , Colin R. Mackenzie , Carole Grad
发明人： Jamshid Tanha , Joycelyn Entwistle , Saran Narang , Michael Dan , Colin R. Mackenzie , Howard Kaplan
CPC分类号： C40B40/02 , C07K16/005 , C07K16/3053 , C07K2317/21 , C07K2317/569 , C07K2319/735 , C12N15/1037
摘要： Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and/or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.
摘要翻译： 教导了噬菌体展示文库，其中重组噬菌体群体显示出具有优选的溶解性和/或分子间相互作用特征的多个潜在的结合片段。 还教导了偏置显示库以产生更接近亲本结合片段的优选特征的变体的方法。
-
公开(公告)号：US20050164180A1
公开(公告)日：2005-07-28
申请号：US10451585
申请日：2001-12-21
申请人： Jamshid Tanha , Joycelyn Entwistle , Saran Narang , Michael Dan , Colin Mackenzie , Howard Kaplan , Carole Grad
发明人： Jamshid Tanha , Joycelyn Entwistle , Saran Narang , Michael Dan , Colin Mackenzie , Howard Kaplan , Carole Grad
CPC分类号： C40B40/02 , C07K16/005 , C07K16/3053 , C07K2317/21 , C07K2317/569 , C07K2319/735 , C12N15/1037
摘要： Phage display libraries are taught in which the recombinant phage population displays a plurality of potential binding fragments having preferred characteristics of solubility and/or intermolecular interaction. Also taught are methods of biasing display libraries to produce variants which more closely approximate the preferred characteristics of the parental binding fragment.
摘要翻译： 教导了噬菌体展示文库，其中重组噬菌体群体显示出具有优选的溶解性和/或分子间相互作用特征的多个潜在的结合片段。 还教导了偏置显示库以产生更接近亲本结合片段的优选特征的变体的方法。
-
3.发明授权Cytotoxins comprising modified bouganin toxin for the treatment of cancer 有权细胞毒素包含改良的bouganin毒素用于治疗癌症公开(公告)号：US08716234B2
公开(公告)日：2014-05-06
申请号：US12784820
申请日：2010-05-21
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
IPC分类号： A61P35/00
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
公开(公告)号：US08383117B2
公开(公告)日：2013-02-26
申请号：US11570198
申请日：2005-06-10
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Georges Bosc , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Denis Georges Bosc , Francina C. Chahal
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/2884 , A61K38/00 , A61K39/39558 , A61K45/06 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K2039/505 , C07K14/415 , C07K16/30 , C07K16/3015 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/626 , C07K2317/77 , C07K2319/55 , C12N9/1077 , G01N33/574 , G01N2333/471 , G01N2333/70585
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a tumor specific antibody. In addition, the invention provides tumor-specific antibodies and immunoconjugates comprising the tumor-specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the tumor-specific antibodies of the invention.
摘要翻译： 本发明提供了肿瘤特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供包含附着于毒素或标记物的肿瘤特异性抗体的肿瘤特异性抗体和免疫缀合物及其方法和用途。 本发明还涉及使用本发明的肿瘤特异性抗体的诊断方法和试剂盒。
-
公开(公告)号：US08697075B2
公开(公告)日：2014-04-15
申请号：US13297783
申请日：2011-11-16
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
IPC分类号： A61K39/00 , A61K39/395 , C07K16/30
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
公开(公告)号：US20100254982A1
公开(公告)日：2010-10-07
申请号：US11722420
申请日：2005-12-21
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
IPC分类号： A61K39/395 , C07K14/00 , C07H21/00 , C12N15/74 , C12N1/21 , C07K16/18 , C07K16/28 , G01N33/574 , A61K38/16 , A61K31/7088 , A61K39/00 , C12Q1/68 , A61P35/00
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
7.发明申请公开(公告)号：US20050238642A1
公开(公告)日：2005-10-27
申请号：US11084080
申请日：2005-03-18
申请人： Matthew Baker , Francis Carr , Koen Hellendoorn , Jeannick Cizeau , Glen MacDonald , Joycelyn Entwistle , Denis Bosc , Nicholas Glover
发明人： Matthew Baker , Francis Carr , Koen Hellendoorn , Jeannick Cizeau , Glen MacDonald , Joycelyn Entwistle , Denis Bosc , Nicholas Glover
IPC分类号： A61K38/00 , A61K38/16 , A61K39/395 , A61K47/48 , A61P35/00 , C07K7/08 , C07K14/415 , C07K16/30 , C07K16/44 , C07K19/00 , C12N15/11 , C12N15/13 , C12N15/29 , C12N15/62
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
公开(公告)号：US08084576B2
公开(公告)日：2011-12-27
申请号：US11722420
申请日：2005-12-21
申请人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
发明人： Nicholas Ronald Glover , Glen Christopher MacDonald , Joycelyn Entwistle , Jeannick Cizeau , Francina C. Chahal
CPC分类号： A61K39/0011 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/21 , C07K2317/41 , C07K2317/51 , C07K2317/55 , C07K2317/565 , C07K2317/92 , G01N33/57488 , G01N2500/10
摘要： The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof.
摘要翻译： 本发明提供癌特异性抗体的重链和轻链互补决定区的氨基酸和核酸序列。 此外，本发明提供癌症特异性抗体和包含附着于毒素或标记物的癌症特异性抗体的免疫缀合物及其方法和用途。 本发明还涉及使用本发明的癌症特异性抗体的诊断方法和试剂盒。 此外，本发明提供了一种新的癌症相关抗原及其用途。
-
9.发明申请公开(公告)号：US20100254964A1
公开(公告)日：2010-10-07
申请号：US12784820
申请日：2010-05-21
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
10.发明授权公开(公告)号：US07339031B2
公开(公告)日：2008-03-04
申请号：US11084080
申请日：2005-03-18
申请人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
发明人： Matthew Baker , Francis J. Carr , Koen Hellendoorn , Jeannick Cizeau , Glen Christopher MacDonald , Joycelyn Entwistle , Denis Georges Bosc , Nicholas Ronald Glover
CPC分类号： C07K16/30 , A61K38/00 , A61K47/6825 , A61K2039/505 , C07K14/415 , C07K2317/34 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/55
摘要： The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
摘要翻译： 本发明提供具有生物活性的bouganin蛋白质的修饰形式，与非修饰的bouganin蛋白质相比，活化人类T细胞的倾向降低。 本发明还提供了与非修饰的T细胞表位肽相比，bouganin的T细胞表位肽和bouganin的修饰的T细胞表位肽，其具有降低的活化人T细胞的倾向。 本发明还提供了具有与附着于改良的bouganin蛋白的癌细胞结合的配体的细胞毒素。 还提供了使用本发明的细胞毒素和用于治疗人类癌症的药物组合物来抑制或破坏哺乳动物癌细胞的方法。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.034 秒)
